fda glp-1 warning october 2025 GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists FDA telehealth crackdown highlights role

When to talk to your provider If you have reached the maximum recommended dose and maintained it for 12 to 16 weeks without achieving at least 5% body weight loss, a conversation with your provider is warranted

Beyond lipid metabolism, GLP-1RAs exert profound effects on mitochondrial homeostasis in retinal neurons

Before giving your child any supplement for weight management or metabolic health, speak with your child's pediatrician or pediatric endocrinologist

Our bariatric medicine specialist, Dr

Additionally, the FDA says Novo Nordisk failed to develop written procedures for reporting postmarketing adverse drug experiences (ADEs)

Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K/Akt/GSK-3 pathway